Global Enzymatic DNA Synthesis Market — Powering the Next Wave of Genomic Innovation

Global Enzymatic DNA Synthesis Market

The global enzymatic DNA synthesis market is rapidly reshaping the field of precision medicine and synthetic biology. Once considered an emerging alternative to chemical methods, enzymatic synthesis has now gained strong momentum with expanding R&D applications, rising adoption in healthcare, and growing funding in research and development. Increasing demand for personalized medicine, genome editing, and faster gene synthesis is propelling market growth worldwide, making enzymatic approaches central to the next era of biotechnology.

Market Definition

Enzymatic DNA synthesis (EDS) is a method for creating custom DNA sequences using enzymes instead of the harsh chemical reagents employed in traditional chemical synthesis. This process operates under mild, aqueous conditions and uses an enzyme, typically a variant of Terminal Deoxynucleotidyl Transferase (TdT), to add nucleotides one at a time to a growing DNA chain. The enzymatic DNA synthesis founds its application across healthcare, diagnostics, agriculture, and even data storage, where DNA is explored as a next-generation information medium.

Global Enzymatic DNA Synthesis Market: Growth Anchored in Automation

• The global enzymatic DNA synthesis market was valued at approximately USD 295.86 million in 2024 and is projected to surge to around USD 2,253.41 million by 2032, expanding at a robust CAGR of 28.89% during the forecast period from 2025 to 2032. In 2024, North America led the market, accounting for roughly 49.03% of global revenue, while the Europe market is expected to experience significant growth, bolstered by increasing demand for rapid, high-fidelity DNA synthesis, expanding applications in synthetic biology and therapeutics area, and sustained investments in biotechnology infrastructure.
• A key catalyst for global growth is the rising emphasis on precision medicine, where enzymatic DNA synthesis plays a pivotal role in enabling the rapid and reliable production of customized genetic sequences essential for targeted therapies, advanced diagnostics, and genomic research. Ongoing technological advancements, strategic industry collaborations, and the broadening scope of synthetic biology applications and therapeutic research are expected to further strengthen market momentum over the forecast horizon.
• Automation: It is emerging as a key growth driver in the enzymatic DNA synthesis market, enabling higher efficiency, accuracy, and scalability in DNA production processes. By integrating advanced automated platforms, laboratories and biotech companies can significantly reduce human error, accelerate turnaround times, and lower operational costs. This technological shift not only supports large-scale synthetic biology and genomics projects but also enhances the feasibility of precision medicine applications by providing rapid, reliable, and customized DNA sequences. As automation continues to streamline workflows and improve reproducibility, it is expected to play a pivotal role in expanding the adoption of enzymatic DNA synthesis across research, diagnostics, and therapeutic development.
• The integration of artificial intelligence (AI) with automation is transforming the enzymatic DNA synthesis market by enabling smarter, data-driven decision-making and optimized synthesis workflows. AI-powered algorithms can analyze vast datasets to predict sequence behavior, identify potential errors, and design optimized protocols, thereby improving the accuracy and success rate of DNA synthesis. When combined with automation, these capabilities allow for high-throughput, error-free, and cost-efficient production of genetic material.
• Companies such as Ansa Biotechnologies, DNA Script, and Evonetix are increasingly leveraging AI-driven platforms to enhance precision, accelerate R&D, and support applications in synthetic biology, drug discovery, and personalized medicine. This convergence of AI and automation is expected to foster innovation, reduce time-to-market for therapeutics, and further expand the scope of enzymatic DNA synthesis in healthcare and biotechnology.
• Advancements in Synthetic Biology and Genomics: Breakthroughs in synthetic biology and genomics are creating robust opportunities for enzymatic DNA synthesis. Synthetic biology applications such as pathway engineering, genome recoding, and the design of novel biological systems depend on access to long, accurate DNA sequences.
• Similarly, the rapid expansion of genomic research, including large-scale sequencing projects and gene function studies, requires reliable synthesis technologies. Unlike traditional chemical methods, enzymatic DNA synthesis offers scalability, environmental sustainability, and higher sequence accuracy, making it an indispensable tool for advancing innovation in these scientific disciplines.
• For example, companies like Ginkgo Bioworks and Zymergen engineer microbes to produce sustainable materials, fragrances, or biofuels, which require long and precise DNA constructs. Similarly, large-scale genomic projects such as the Human Pangenome Project need error-free DNA synthesis for sequencing validation and functional studies.
• Increasing Investments and Collaborations: The enzymatic DNA synthesis industry is benefiting from strong financial backing and collaborative initiatives. Governments, venture capital firms, and private investors are providing significant funding to accelerate innovation in synthetic biology and DNA manufacturing technologies.
• In parallel, strategic partnerships among biotechnology companies, pharmaceutical firms, and research institutions are expediting the development and commercialization of next-generation synthesis platforms. These collaborations foster knowledge sharing, improve scalability, and strengthen supply chains, ultimately helping the industry to overcome traditional bottlenecks and expand into new markets.
• For example, Twist Bioscience partnered with Illumina to advance next-generation sequencing applications, while DNA Script secured substantial funding to accelerate its enzymatic synthesis platform for decentralized DNA printing. Such collaborations combine technical expertise and capital to scale production, broaden market reach, and accelerate innovation, directly boosting market growth.
• Companies are developing novel polymerases capable of producing longer DNA strands with higher fidelity, while automation and microfluidic systems are making synthesis faster and scalable. Integration of artificial intelligence is further improving design accuracy, while advancements in DNA printing and benchtop synthesizers are enabling labs to produce DNA on demand without relying on external providers.
• Global Enzymatic DNA Synthesis – Restraining Factors
• High Cost of Technology: Enzymatic DNA synthesis is an emerging field, and the cost of developing and scaling these technologies remains significantly higher compared to traditional phosphoramidite chemical synthesis. The enzymes required are often engineered proteins that need complex production and purification processes.
• Additionally, specialized instruments and proprietary platforms are not widely available, which keeps costs high for early adopters. This pricing gap limits accessibility for smaller research institutes and startups, thereby slowing market penetration.
• Companies like DNA Script (France) and Molecular Assemblies (U.S.) have developed benchtop enzymatic DNA printers and synthesis platforms, but these systems currently carry premium pricing. While large pharma and biotech firms can afford to integrate them into R&D workflows, academic labs or early-stage biotech startups often still outsource to cheaper chemical synthesis providers, delaying widespread adoption.
• Technical Limitations in Accuracy and Length: Although enzymatic methods offer a greener and potentially faster approach, their accuracy and scalability still lag behind chemical synthesis. Challenges include higher error rates in incorporating nucleotides, difficulties in synthesizing longer DNA fragments without introducing mutations, and issues with reproducibility in high-throughput settings. Until these limitations are resolved, enzymatic synthesis struggles to replace well-established chemical methods for applications requiring long, error-free sequences, such as gene therapy or synthetic biology.
• Ansa Biotechnologies (U.S.) is working on enzymatic synthesis for longer DNA constructs with higher fidelity, but the technology is still under development and has not yet reached the throughput or error-rate levels of established chemical processes. Researchers working on CRISPR libraries or synthetic genomes often continue using chemical synthesis because it delivers consistent, validated results at scale.
• Stringent Regulatory Frameworks: DNA synthesis technologies face strict regulatory oversight because of their potential misuse, especially in creating harmful pathogens or dual-use genetic materials. Agencies and organizations such as the International Gene Synthesis Consortium (IGSC) enforce mandatory sequence screening to prevent unauthorized orders of pathogenic DNA. While necessary for biosecurity, these requirements increase compliance costs, slow product delivery, and create hurdles for smaller firms that may lack resources to meet such standards efficiently.
• In 2020, regulatory authorities increased scrutiny on synthetic DNA suppliers to prevent the synthesis of SARS-CoV-2 genetic fragments for unauthorized use. This forced DNA synthesis companies, including enzymatic pioneers, to adopt enhanced screening systems, extending delivery timelines and raising operational costs. Such measures, while essential for safety, add complexity to commercialization.
• Competition from Established Chemical DNA Synthesis: Chemical DNA synthesis has been the gold standard for decades, with robust supply chains, optimized manufacturing processes, and well-documented regulatory approval pathways. Customers are hesitant to shift from a proven system to a new, less-tested alternative unless there are clear, demonstrated advantages in speed, cost, and accuracy. This entrenched dominance of chemical synthesis creates a significant barrier for enzymatic DNA synthesis to rapidly gain market share.
• Some market leader in chemical DNA synthesis, continues to dominate the market by offering cost-effective, scalable synthesis of long DNA fragments. Even though enzymatic methods are marketed as sustainable and potentially faster, many pharmaceutical and biotech companies prefer sticking with Twist and similar providers due to reliability, scalability, and regulatory familiarity, delaying the switch to enzymatic platforms.
• Regional Spotlight – North America to witness highest growth due to rise in technological adoption
• North America: North America dominates the global enzymatic DNA synthesis market, largely due to its robust biotechnology ecosystem, advanced research infrastructure, and strong government and private funding in genomics and synthetic biology. The U.S. is at the forefront, with significant investments from institutions like the National Institutes of Health (NIH) and venture capital funding fueling the growth of startups and established players such as DNA Script, Molecular Assemblies, Ansa Biotechnologies, and GenScript.
• Additionally, the rising adoption of precision medicine and CRISPR-based applications in the region creates strong demand for rapid and accurate DNA synthesis methods. The U.S. FDA’s supportive regulatory environment for biotech innovations further encourages commercialization, positioning North America as the global leader in this space.
• Europe: Europe is emerging as a key contributor, with countries like the UK, Germany, and France driving growth through heavy investments in synthetic biology and genome engineering research. The European Commission’s Horizon Europe program and other funding initiatives are supporting biotech R&D, particularly focusing on sustainable and eco-friendly DNA synthesis alternatives.
• Academic-industry collaborations, such as partnerships between biotech startups and major pharmaceutical firms, are fostering adoption of enzymatic DNA synthesis in drug discovery and diagnostics.
• Asia-Pacific: The Asia-Pacific region is projected to witness the fastest growth, driven by rising investments in biotechnology and genomics across China, Japan, and India. China has launched large-scale national initiatives to boost synthetic biology research, while Japan is advancing DNA synthesis for regenerative medicine and precision healthcare. India’s growing biotech sector, supported by government programs like Biotechnology Industry Research Assistance Council (BIRAC), is also beginning to explore enzymatic synthesis for diagnostics and agricultural biotechnology.

Major Companies and Competitive Landscape

The enzymatic DNA synthesis market is a mix of well-established biotech leaders and fast-growing startups, making it both competitive and highly innovative. Big names like DNA Script, Molecular Assemblies, Ansa Biotechnologies, Twist Bioscience, and GenScript are leading the way by developing advanced enzymatic synthesis technologies that are faster, more accurate, and more eco-friendly than traditional chemical methods. Their heavy investment in research and product development is helping the technology move from lab use to wider commercial adoption.

Alongside these leaders, a new wave of smaller biotech companies is bringing fresh ideas to the market. Many of them are introducing platform-based solutions, automation-driven systems, and custom synthesis services that meet the growing demand from research labs, pharmaceutical companies, and industrial biotech firms. This influx of new players is increasing competition but also pushing the market forward, especially in areas like precision medicine, gene editing, and synthetic biology.

To stay ahead, companies are focusing on partnerships, licensing deals, and fundraising to speed up innovation and bring products to market faster. Startups are teaming up with big pharma and biotech firms to integrate enzymatic DNA synthesis into drug discovery and development. Another key shift is the industry’s growing emphasis on sustainability—enzymatic methods are gaining traction because they’re cleaner and safer for the environment compared to older chemical synthesis techniques.

Recent Developments:

• In January 2025, Molecular Assemblies’ proprietary Fully Enzymatic Synthesis™ technology was acquired by Maravai LifeSciences. This move enables Maravai’s TriLink BioTechnologies division to enhance its capabilities in producing mRNA and CRISPR-based therapies using enzymatic DNA synthesis.
• On February 3, 2025, DNA Script launched a new enzymatic DNA synthesis offering that breaks sequence complexity and length barriers. It delivers exceptional versatility, enabling synthesis of challenging regions such as high-GC content, poly-A/poly-T stretches, inverted terminal repeats (ITRs), untranslated regions (UTRs), and promoter sequences.
• On February 6, 2025, scientists in Paris advanced enzymatic DNA synthesis to streamline mRNA vaccine production. Supported by USD 4.7 million in CEPI funding, DNA Script is working to automate synthetic DNA template manufacturing—accelerating vaccine timelines and improving access, especially in the Global South (in Latin America, Africa, Asia, and Oceania.)

Conclusion:

The global enzymatic DNA synthesis market is poised to transform the future of biotechnology, precision medicine, and synthetic biology. Although still at an early stage compared to traditional chemical synthesis, its advantages in accuracy, sustainability, and integration with automation and AI are driving rapid adoption. While challenges such as high costs, scalability issues, and regulatory complexities remain, increasing investments, strategic collaborations, and technological advancements are strengthening market growth. With North America leading in adoption, Europe focusing on sustainable innovation, and Asia-Pacific emerging as the fastest-growing hub, the market is set for strong global expansion. As demand for personalized medicine, gene editing, and synthetic biology continues to rise, enzymatic DNA synthesis is expected to transition from a promising alternative to a mainstream technology, fueling the next wave of genomic and therapeutic breakthroughs.

At Advantia Business Consulting, we tailor Enzymatic DNA Synthesis (EDS) market intelligence to your priorities. Building on the insights above — from automation and AI-enabled workflows to precision-medicine applications, funding-led partnerships, regional adoption, and biosecurity-driven regulation—we can provide country-level sizing, technology benchmarking (TdT variants, benchtop EDS platforms), pricing and capacity tracking, and competitor portfolio reviews (e.g., DNA Script, Molecular Assemblies, Ansa Biotechnologies, Twist Bioscience, GenScript). Deliverables are available as Excel factbooks with pivot tables and executive-ready presentations aligned to your KPIs.

Follow us on: Facebook, Twitter, Instagram and LinkedIn.